Blood group antigen fusion polypeptides and methods of use thereof
The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection.
1. A fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide:
(a) is a mucin polypeptide and
(b) is glycosylated by an α1,2 fucosyltransferase and the second polypeptide comprises at least a region of an immunoglobulin polypeptide.
2. The fusion polypeptide of claim 1 , wherein the first polypeptide glycosylated by the α1,2 fucosyltransferase is further glycosylated by an α1,3 N-acetylgalactosaminyltransferase or an α1,3 galactosyltransferase.
3. The fusion polypeptide of claim 1 , wherein the α1,2 fucosyltransferase is a blood group H or Secretor α1,2 fucosyltransferase.
4. The fusion polypeptide of claim 1 , wherein the first polypeptide comprises at least a region of a P-selectin glycoprotein ligand-1.
5. The fusion polypeptide of claim 4 , wherein said first polypeptide includes an extracellular portion of a P-selectin glycoprotein ligand-1.
6. The fusion polypeptide of claim 1 , wherein the second polypeptide comprises a region of a heavy chain immunoglobulin polypeptide.
7. The fusion polypeptide of claim 6 , wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.
8. The fusion polypeptide of claim 1 , wherein the fusion polypeptide is a dimer.